Voyager Therapeutics
$4
59
+$0.1+2.56% Monday 21:00
Statistics
Day High
4.09
Day Low
3.88
52W High
5.78
52W Low
2.65
Volume
680,880
Avg. Volume
523,280
Mkt Cap
222.4M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
10MarExpected
Expected EPS
-0.510805
Actual EPS
N/A
Financials
-81.25%Profit Margin
Unprofitable160MRevenue
-130MNet Income
Analyst Ratings
$25.00Average Price Target
The highest estimate is 25.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow VYGR. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
PTC Therapeutics
PTCT
Mkt Cap5.4B
Novartis
NVS
Mkt Cap237.61B
Pfizer
PFE
Mkt Cap140.15B
Abeona Therapeutics
ABEO
Mkt Cap246.65M
About
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Employees
172
Country
US
ISIN
US92915B1061
Listings
0 Comments
Share your thoughts
FAQ
What is Voyager Therapeutics stock price today?▼
The current price of VYGR is $4 USD — it has increased by +2.56% in the past 24 hours. Watch Voyager Therapeutics stock price performance more closely on the chart.
What is Voyager Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Voyager Therapeutics stocks are traded under the ticker VYGR.
Is Voyager Therapeutics stock price growing?▼
VYGR stock has risen by +1.52% compared to the previous week, the month change is a -0.74% fall, over the last year Voyager Therapeutics has showed a -24.95% decrease.
What is Voyager Therapeutics market cap?▼
Today Voyager Therapeutics has the market capitalization of 222.4M
When is the next Voyager Therapeutics earnings date?▼
Voyager Therapeutics is going to release the next earnings report on March 10, 2026.
What were Voyager Therapeutics earnings last quarter?▼
VYGR earnings for the last quarter are -0.47 USD per share, whereas the estimation was -0.52 USD resulting in a +9.77% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Voyager Therapeutics revenue for the last year?▼
Voyager Therapeutics revenue for the last year amounts to 160M USD.
What is Voyager Therapeutics net income for the last year?▼
VYGR net income for the last year is -130M USD.
How many employees does Voyager Therapeutics have?▼
As of February 03, 2026, the company has 172 employees.
In which sector is Voyager Therapeutics located?▼
Voyager Therapeutics operates in the Health Care sector.
When did Voyager Therapeutics complete a stock split?▼
Voyager Therapeutics has not had any recent stock splits.
Where is Voyager Therapeutics headquartered?▼
Voyager Therapeutics is headquartered in Lexington, US.